Table 2.
Change from baseline in MADRS total score and HAM-D17 total score
| Difference from placeboa | ||||
|---|---|---|---|---|
| Placebo group (n = 177) | Quetiapine XR 300 mg group (n = 179) | LS mean (two-sided 95% CI) | P value | |
| MADRS total score | ||||
| Baseline | 30.8 (6.4) | 30.9 (6.9) | – | – |
| End of treatment | 20.6 (11.9) | 18.2 (11.2) | – | – |
| Change from Baseline | − 10.1 (10.9) | − 12.6 (11.4) | − 2.4 (− 4.7, − 0.2) | 0.034 |
| HAM-D17 total score | ||||
| Baseline | 23.1 (2.8) | 23.0 (3.0) | – | – |
| End of treatment | 14.7 (8.3) | 12.9 (7.1) | – | – |
| Change from Baseline | − 8.4 (7.6) | − 10.1 (7.6) | − 1.7 (− 3.3, − 0.1) | 0.033 |
Mean (SD)
MADRS Montgomery-Åsberg Depression Rating Scale, HAM-D17 Hamilton Depression Scale 17-Item
aAnalysis of covariance (ANCOVA) including treatment and bipolar diagnosis (bipolar I disorder or bipolar II disorder) as fixed factors and baseline as a covariate